- Special Contributor, Guide to Biosimilars Litigation and Regulation in the U.S., 2020-2021 ed., published by Thomson Reuters, January 2021
- Speaker, “Clinical Trials, Marketing, and Labeling: Strategies for Proving and Defending Induced Infringement of Biosimilars,” Webinar, October 2020
- Contributor, “Guide to Biosimilars Litigation and Regulation in the U.S., 2019-2020 ed.,” published by Thomson Reuters, November 2019
- Speaker, “What Can You Be with a PHD?: A Science & Technology Career Symposium in Partnership with Springer Nature,” October 2019
Beth Ashbridge, Ph.D.
Beth Ashbridge is an associate in the firm’s Litigation Department and a member of its Intellectual Property practice. She contributes to the firm's work in patent litigation, patent opinions and due diligence. Dr. Ashbridge joined Goodwin in 2013 as a Science Advisor and later qualified as a J.D.
In 2019, Dr. Ashbridge graduated from the J.D. part-time evening program at Fordham University School of Law with honors (cum laude), and was extended the Paul Fuller Scholar Designation. Dr. Ashbridge has also been granted limited recognition to practice in patent matters before the U.S. Patent and Trademark Office.
Dr. Ashbridge has been involved in several Hatch-Waxman and BPCIA patent litigation cases on both the brand and generic side. Dr. Ashbridge is also an active contributor to the firm’s biosimilars blog, Big Molecule Watch, which is dedicated to providing resources and observations through Goodwin’s active watch of the world of biologics, biosimilars and the Biologics Price Competition and Innovation Act (BPCIA). Dr. Ashbridge is an editor of Goodwin’s Guide to Biosimilars Litigation and Regulation in the U.S., which provides expert guidance and practical know-how for lawyers working in this burgeoning area of the law.
Dr. Ashbridge brings to her practice an exceptional combination of patent law expertise and technical proficiency in the pharmaceutical and biotechnology fields. Prior to joining Goodwin, Dr. Ashbridge carried out her graduate research in the Chemical Biology program at the Department of Chemistry, University of Cambridge, under the supervision of Sir Professor Shankar Balasubramanian. Dr. Ashbridge worked on several projects involving the in vitro protein expression and reconstitution, and then subsequent single molecule analysis of the human telomerase ribonucleoprotein complex.
Following her graduate studies, Dr. Ashbridge worked under the guidance of Dr. Malcolm A.S. Moore as a Research Fellow in the Cell Biology Program at Memorial Sloan-Kettering Cancer Center in New York City. Using her cell and molecular biology training, Dr. Ashbridge worked on several projects investigating the importance of the enzyme telomerase in lung and pancreatic cancers, and the role of this complex in double cord blood transplantation.
Fordham University School of Law
(cum laude; Paul Fuller Scholar; Activities: Urban Law Journal)
University of Cambridge